Evolutionary Rationale for Phages as Complements of Antibiotics

Trends in Microbiology

Volumn 24, Issue 4, 2016, Pages 249-256

  Torres Barceló, Clara ^a   Hochberg, Michael E ^a,b  

^a UNIV MONTPELLIER   (France)

^b SANTA FE INSTITUTE   (United States)

Author keywords

Antibiotic resistance; Combined therapies; Evolution; Phage therapy

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; ENROFLOXACIN; GENTAMICIN; KANAMYCIN; LINEZOLID; MEROPENEM; STREPTOMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BACTERIOPHAGE; BIOFILM; BURKHOLDERIA CEPACIA; DRUG POTENTIATION; ESCHERICHIA COLI; HORIZONTAL GENE TRANSFER; HUMAN; KLEBSIELLA PNEUMONIAE; LISTERIA MONOCYTOGENES; MOLECULAR EVOLUTION; MYOVIRIDAE; NONHUMAN; PODOVIRIDAE; PRIORITY JOURNAL; PSEUDOMONAS PHAGE; QUORUM SENSING; SALMONELLA PHAGE; SIPHOVIRIDAE; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; DRUG EFFECTS; EVOLUTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; MULTIDRUG RESISTANCE; PHAGE THERAPY; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL EVOLUTION; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; PHAGE THERAPY;

EID: 84961213584     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2015.12.011     Document Type: Review

References (60)

1. Reardon S. Dramatic rise seen in antibiotic use. Nature 2015, Published online September 17, 2015. 10.1038/nature.2015.18383.
2. Laxminarayan R., et al. Antibiotic resistance - the need for global solutions. Lancet Infect. Dis. 2013, 13:1057-1098.
3. Okeke I.N. Poverty and root causes of resistance in developing countries. Antimicrobial Resistance in Developing Countries 2010, 27-35. Springer. A. Sosa, J. de (Eds.).
4. Reardon S. Antibiotic resistance sweeping developing world. Nature 2014, 509:141-142.
5. Ling L.L., et al. A new antibiotic kills pathogens without detectable resistance. Nature 2015, 517:455-459.
6. Cociancich S., et al. The gyrase inhibitor albicidin consists of p-aminobenzoic acids and cyanoalanine. Nat. Chem. Biol. 2015, 11:195-197.
7. Baumann S., et al. Cystobactamids: Myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity. Angew. Chem. Int. Ed. Egl. 2014, 53:14605-14609.
8. Leclercq R., et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 1988, 319:157-161.
9. Read A.F., et al. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10871-10877.
10. Masui K. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis 2013, 34:725-738.
11. Volberding P.A., Deeks S.G. Antiretroviral therapy and management of HIV infection. Lancet 2010, 376:49-62.
12. Worthington R.J., Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 2013, 31:177-184.
13. Betts A., et al. Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1. Evol. Appl. 2013, 6:1054-1063.
14. Chanishvili N. Phage therapy-history from Twort and d'Herelle through Soviet experience to current approaches. Adv. Virus Res. 2012, 83:3-40.
15. Kutateladze M., Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010, 28:591-595.
16. Endersen L., et al. Phage therapy in the food industry. Annu. Rev. Food Sci. Technol. 2014, 5:327-349.
17. Huff W.E., et al. Therapeutic efficacy of bacteriophage and baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers. Poult. Sci. 2004, 83:1944-1947.
18. Carlton R.M., et al. P100 for control of Listeria monocytogenes in foods: Genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul. Toxicol. Pharm. 2005, 43:301-312.
19. Oliveira M., et al. Biopreservative methods to control the growth of foodborne pathogens on fresh-cut lettuce. Int. J. Food Microbiol. 2015, 214:4-11.
20. Young R., Gill J.J. Phage therapy redux - What is to be done?. Science 2015, 350:1163-1164.
21. Nobrega F.L., et al. Revisiting phage therapy: new applications for old resources. Trends Microbiol. 2015, 23:185-191.
22. Wright A., et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 2009, 34:349-357.
23. Kingwell K. Bacteriophage therapies re-enter clinical trials. Nat. Rev. Drug Discov. 2015, 14:515-516.
24. Crain C.M., et al. Interactive and cumulative effects of multiple human stressors in marine systems. Ecol. Lett. 2008, 11:1304-1315.
25. Piggott J.J., et al. Reconceptualizing synergism and antagonism among multiple stressors. Ecol. Evol. 2015, 5:1538-1547.
26. Lebeis S.L., Kalman D. Aligning antimicrobial drug discovery with complex and redundant host-pathogen interactions. Cell Host Microbe 2009, 5:114-122.
27. Verma V., et al. Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment. Biofouling 2010, 64:1212-1218.
28. Chhibber S., et al. Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS ONE 2013, 8:e56022.
29. Zhang Q.G., Buckling A. Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evol. Appl. 2012, 5:575-582.
30. Kirby A.E. Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS ONE 2012, 7:e51017.
31. Chaturongakul S., Ounjai P. Phage-host interplay: examples from tailed phages and Gram-negative bacterial pathogens. Front. Microbiol. 2014, 5:442.
32. Torres-Barceló C., et al. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS ONE 2014, 9:e106628.
33. Birger R.B., et al. The potential impact of coinfection on antimicrobial chemotherapy and drug resistance. Trends Microbiol. 2015, 23:537-544.
34. McVicker G., et al. Clonal expansion during Staphylococcus aureus infection dynamics reveals the effect of antibiotic intervention. PLoS Pathog. 2014, 10:e1003959.
35. Lehman S.M., Donlan R.M. Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model. Antimicrob. Agents Chemother. 2015, 59:1127-1137.
36. Krueger A.P., et al. Observations on the effect of penicillin on the reaction between phage and staphylococci. J. Gen. Physiol. 1948, 31:477-488.
37. Comeau A.M., et al. Phage-antibiotic synergy (PAS): β-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE 2007, 2:e799.
38. Ryan E.M., et al. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol. Med. Microbiol. 2012, 65:395-398.
39. Kaur S., et al. Methicillin-resistant Staphylococcus aureus phage plaque size enhancement using sublethal concentrations of antibiotics. Appl. Environ. Microbiol. 2012, 78:8227-8233.
40. Kamal F., Dennis J.J. Burkholderia cepacia complex phage-antibiotic synergy (PAS): Antibiotics stimulate lytic phage activity. Appl. Environ. Microbiol. 2015, 81:1132-1138.
41. Knezevic P., et al. Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Res. Microbiol. 2013, 164:55-60.
42. Kouyos R.D., et al. The path of least resistance: aggressive or moderate treatment?. Proc. Biol. Sci. 2014, 281:20140566.
43. Pena-Miller R., et al. When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. PLoS Biol. 2013, 11:e1001540.
44. Baharoglu Z., Mazel D. Vibrio cholerae triggers SOS and mutagenesis in response to a wide range of antibiotics: a route towards multiresistance. Antimicrob. Agents Chemother. 2011, 55:2438-2441.
45. Ram G., et al. Staphylococcal pathogenicity island interference with helper phage reproduction is a paradigm of molecular parasitism. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:16300-16305.
46. Bearson B.L., Brunelle B.W. Fluoroquinolone induction of phage-mediated gene transfer in multidrug-resistant Salmonella. Int. J. Antimicrob. Agents 2015, 46:201-204.
47. Lu T.K., Collins J.J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4629-4634.
48. Levin B.R., Bull J.J. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2004, 2:166-173.
49. Nichol D., et al. Steering evolution with sequential therapy to prevent the emergence of bacterial antibiotic resistance. PLoS Comput. Biol. 2015, 11:e1004493.
50. Pages J.M., et al. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat. Rev. Microbiol. 2008, 6:893-903.
51. Pollitt E.J.G., et al. Cooperation, quorum sensing, and evolution of virulence in Staphylococcus aureus. Infect. Immun. 2014, 82:1045-1051.
52. Jousset A., et al. Predators promote defence of rhizosphere bacterial populations by selective feeding on non-toxic cheaters. ISME J. 2009, 3:666-674.
53. Diard M., et al. Antibiotic treatment selects for cooperative virulence of Salmonella Typhimurium. Curr. Biol. 2014, 24:2000-2005.
54. Letellier L., et al. Main features on tailed phage, host recognition and DNA uptake. Front. Biosci. 2004, 9:1228-1339.
55. Roux D., et al. Fitness cost of antibiotic susceptibility during bacterial infection. Sci. Transl. Med. 2015, 7:297ra114.
56. Fernandez-Cuenca F., et al. Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like. Int. J. Antimicrob. Agents 2011, 38:548-549.
57. Laanto E., et al. Phage-driven loss of virulence in a fish pathogenic bacterium. PLoS ONE 2012, 7:e53157.
58. Evans T.J., et al. Exploitation of a new flagellatropic phage of Erwinia for positive selection of bacterial mutants attenuated in plant virulence: towards phage therapy. J. Appl. Microbiol. 2010, 108:676-685.
59. Seed K.D., et al. Evolutionary consequences of intra-patient phage predation on microbial populations. Elife 2014, 26:e03497.
60. Beceiro A., et al. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?. Clin. Microbiol. Rev. 2013, 26:185-230.